Pharma companies directory 2026

    Pharmaceutical Companies in Indonesia

    Indonesia is the largest pharmaceutical market in ASEAN by value, and it is also the most domestically owned: locally headquartered groups such as Kalbe Farma, Dexa Medica, Sanbe and Tempo Scan account for the greater part of prescription and OTC sales to a population of more than 280 million.

    Three institutions shape how a medicine reaches an Indonesian patient. BPOM issues the marketing authorisation and inspects every plant; BPJS Kesehatan, the single payer behind the JKN national insurance scheme, decides which molecules sit on the national formulary and at what price; and the LKPP e-catalogue converts that formulary into the price list from which public hospitals and community health centres buy. Around this public core sits a large private economy of hospital groups, pharmacy chains, herbal and consumer-health brands, and a network of licensed wholesalers known as PBFs that move product across an archipelago of 17,000 islands. The companies below are the manufacturers, multinational affiliates and distribution arms that BioNixus tracks when a client asks who really holds share in a therapy area in Jakarta, Surabaya or Medan.

    Updated September 2026 · Badan Pengawas Obat dan Makanan (BPOM) — registered drug products and licensed pharmaceutical industries as of September 2026 · 22 named accounts

    Request a proposal for IndonesiaBrowse the 22 companies

    $6.4bn+

    Prescription and OTC pharmaceutical sales, 2024 estimate

    240

    Pharmaceutical manufacturers licensed by BPOM, of which ~160 active (2024)

    270m+

    JKN members covered by BPJS Kesehatan

    ~90%

    Share of active pharmaceutical ingredients imported

    Named accounts

    Top pharmaceutical companies in Indonesia

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Badan Pengawas Obat dan Makanan (BPOM) — registered drug products and licensed pharmaceutical industries (as of 2026-09-03).
    #CompanyHQ
    01Badan Pengawas Obat dan Makanan (BPOM)Jakarta
    02BPJS KesehatanJakarta
    03Kalbe FarmaJakarta
    04Kimia FarmaJakarta
    05Bio FarmaBandung
    06Dexa MedicaTangerang
    07Sanbe FarmaBandung
    08Tempo Scan PacificJakarta
    09Soho Global HealthJakarta
    10PhaprosSemarang
    11IndofarmaBekasi
    12CombipharJakarta
    13Pharos IndonesiaJakarta
    14Novell Pharmaceutical LaboratoriesJakarta
    15Darya-Varia LaboratoriaJakarta
    16Pfizer IndonesiaJakarta
    17Sanofi IndonesiaJakarta
    18Novartis IndonesiaJakarta
    19PT Merck TbkJakarta
    20Takeda IndonesiaJakarta
    21Enseval Putera MegatradingJakarta
    22Anugrah Argon Medica (AAM)Tangerang

    Primary research

    These are the pharmaceutical companies accounts we study in Indonesia

    Need account-level or SKU-level data for a brand in Indonesia? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Indonesia?

    Primary research, market access & HEOR. Proposals within 48 hours.

    BioNixus research services

    How the market is structured

    How pharmaceutical supply and reimbursement work in Indonesia

    Every product needs a BPOM registration number held by a licensed Indonesian entity, which in practice means a domestic manufacturer, a multinational affiliate with its own industri farmasi licence, or a toll-manufacturing partner such as Kimia Farma, Sanbe or Dexa producing a foreign brand under licence. Imported finished goods then pass through a PBF wholesaler; the largest are captive to the manufacturers themselves, with Enseval serving Kalbe, Anugrah Argon Medica serving Dexa and Kimia Farma Trading serving the state group, while independents such as Parit Padang and Tempo handle third-party principals. Public demand is governed by the Fornas national formulary and the LKPP e-catalogue: once a molecule is listed, provincial hospitals and the 10,000-plus Puskesmas order at the published price, and the lowest-priced generics from Indofarma, Phapros, Hexpharm and Dexa capture volume. Private hospital groups including Siloam, Mitra Keluarga and Hermina negotiate their own formularies and pay for branded generics and originators that JKN does not cover. Retail splits between organised chains, with Kimia Farma Apotek, Century, Guardian, K-24 and Roxy holding a few thousand outlets, and tens of thousands of independent apotek and toko obat that OTC brands reach through FMCG-style general-trade distributors. Local-content (TKDN) rules under Presidential Regulation 26/2023 now weight e-catalogue awards towards domestically manufactured product, which is pushing multinationals into toll agreements rather than pure import.

    Local

    Indonesian-owned manufacturers, both private and state-controlled, that produce branded generics, OTC and herbal lines and hold the majority of e-catalogue and pharmacy volume.

    • Kalbe Farma
    • Kimia Farma
    • Bio Farma
    • Dexa Medica
    • Sanbe Farma
    • Tempo Scan Pacific
    • Soho Global Health
    • Phapros
    • Indofarma
    • Combiphar
    • Pharos Indonesia
    • Novell Pharmaceutical Laboratories

    Multinational

    Innovator affiliates operating with their own industri farmasi licences or toll partners, concentrated in vaccines, oncology, diabetes and the private hospital segment.

    • Pfizer Indonesia
    • Sanofi Indonesia
    • Novartis Indonesia
    • PT Merck Tbk
    • Takeda Indonesia

    Regional

    ASEAN-headquartered groups such as Unilab that own Indonesian subsidiaries or license portfolios to local plants to reach the JKN and pharmacy channels.

    • Darya-Varia Laboratoria

    Distributors & importers

    The captive and independent PBF wholesalers, the national payer and the regulator whose decisions on listing, price and local content set the terms of supply.

    • Badan Pengawas Obat dan Makanan (BPOM)
    • BPJS Kesehatan
    • Enseval Putera Megatrading
    • Anugrah Argon Medica (AAM)

    What is moving

    What is moving the pharmaceutical market in Indonesia

    Local-content rules under Perpres 26/2023

    Preference for domestically manufactured product in e-catalogue awards is redirecting multinationals towards toll agreements with Kimia Farma, Sanbe and Dexa, and is lifting capacity utilisation at plants that can pass GMP audits for licensed brands.

    JKN formulary expansion into chronic and oncology care

    BPJS Kesehatan has widened coverage of diabetes, cardiovascular and cancer therapies, so generic volumes in those classes are growing faster than the market average and creating room for domestic biosimilar producers.

    Consumer-health and herbal demand

    Indonesian shoppers spend heavily on vitamins, herbal jamu-based remedies and cough and cold brands, which supports Tempo Scan, Soho and Combiphar and gives multinationals a reason to invest in self-medication portfolios.

    Digital pharmacy and chain consolidation

    Halodoc, Alodokter and the expansion of Kimia Farma Apotek and K-24 are shifting OTC and chronic-repeat purchases into channels with purchase data, which changes how brands negotiate listing and promotion.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Indonesia

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Indonesia:
    • Brand-share audits in Jakarta, Surabaya, Bandung and Medan pharmacies, reconciling purchase records against PBF invoices to estimate share by molecule for cardiometabolic and antibiotic baskets.
    • E-catalogue landscaping by molecule: listed suppliers, posted prices and provincial hospital uptake, used by generic and biosimilar entrants to size public volume before registration.
    • Prescriber panels with cardiologists, endocrinologists and oncologists in private hospital groups on originator versus branded-generic preference under JKN and out-of-pocket payment.
    • Toll-manufacturing partner assessments: interviews with plant quality heads and multinational supply managers on capacity, GMP status and local-content qualification at Indonesian sites.

    Questions

    Frequently Asked Questions

    Which pharmaceutical companies hold the largest share in Indonesia?

    Domestic groups dominate: Kalbe Farma, Dexa Medica, Sanbe Farma, Tempo Scan and the state-owned Kimia Farma sit at the top of most audited rankings, with Pfizer, Sanofi and Novartis the largest innovator affiliates. The top fifteen companies are generally estimated to account for roughly three-quarters of market value.

    Does a foreign company need a local partner to sell medicines in Indonesia?

    Yes. BPOM registration must be held by an Indonesian licence holder, and finished goods must move through a licensed PBF wholesaler. Most multinationals operate their own affiliate for registration and appoint a PBF for logistics, while local-content rules increasingly favour toll manufacturing at an Indonesian plant.

    How does the LKPP e-catalogue affect pricing?

    Once a molecule is on the Fornas formulary, manufacturers post prices in the e-catalogue and public hospitals and Puskesmas buy at those prices without a separate tender. Competition among generic producers drives prices down, which is why tender specialists such as Indofarma and Phapros operate on thin margins.

    What role do pharmacy chains play in the Indonesian market?

    Kimia Farma Apotek, Century, Guardian, K-24 and Roxy together operate a few thousand outlets and buy centrally, but the majority of retail volume still flows through independent apotek and toko obat. OTC brands therefore need both chain listings and broad general-trade coverage.

    How does BioNixus research pharmaceutical companies in Indonesia?

    BioNixus fields interviews with hospital pharmacists, BPJS-experienced procurement officers and specialists in Jakarta, Surabaya, Bandung and Medan; audits pharmacy purchase records to estimate brand share by city; maps e-catalogue award histories by molecule; and runs prescriber panels to track switching between originators, branded generics and unbranded generics.

    Is this a ranking?

    It is not. Companies appear because they recur in BioNixus fieldwork across Indonesian hospitals and pharmacies and on BPOM and IDX records, and they are grouped by role rather than sorted by revenue. Position in the table should not be read as a statement about size or quality.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Indonesia. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Badan Pengawas Obat dan Makanan (BPOM) — registered drug products and licensed pharmaceutical industries, consulted 2026-09-03. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Indonesia, not size.

    • BPOM statements on licensed pharmaceutical industries and industry maturity, September 2024
    • Indonesia Stock Exchange annual reports for Kalbe Farma, Kimia Farma, Tempo Scan Pacific, Phapros, Darya-Varia and PT Merck Tbk, 2024–2025
    • MarketLine Pharmaceuticals in Indonesia industry profile, 2024; Ministry of Health and Ministry of Industry statements on API import dependence
    • BioNixus Indonesia hospital, pharmacy and prescriber fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Indonesia?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Indonesia?

    Primary research, market access & HEOR. Proposals within 48 hours.